New ALS drug gains FDA approval
May 30, 2017
For the first time in 22 years, a new drug was approved by the FDA to treat ALS, otherwise known as Lou Gehrig’s Disease. Meanwhile, the yearly cost of living with ALS can reach $200,000, and the ALS Association Arizona Chapter is planning a fundraiser to help sufferers of the disease with costs. We’ll hear from Dr. Jeremy Shefner, professor and chair of neurology and senior vice president at Barrow Neurological Institute, and Taryn Norley, executive director for the ALS Association Arizona Chapter.